StoneX Maintains Buy on OmniAb, Raises Price Target to $6
10/7/2026
Impact: 60
Healthcare
StoneX analyst Robert Wasserman has maintained a Buy rating on OmniAb (NASDAQ: OABI) and raised the price target from $4 to $6. This adjustment reflects a positive outlook for the company's performance.
AI summary, not financial advice
Share: